Browse studies

Find your next paid study

173 recruiting studies matching your filters

Evaluation of the Distribution of CM500 in Healthy Volunteers and Patients With Cancer

The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, \[64Cu\]CM500 and \[68Ga\]CM500, for Positron Emission Tomo…

Bladder CancerGliomaGlioblastoma (GBM)+13 more

Estimated

~$10 – $8,750

Lumina Pharmaceuticals IncNCT07781852

Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunteers and Urothelial Cancer Patients

Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes …

Bladder CancerUrinary Tract CancerUrothelial Cancer+1 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02379429

Phase 1

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors

The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \[177Lu\]Lu-DWJ155 and the safety …

Breast CancerNon-small Cell Lung Cancer (NSCLC)Gastric/Gastroesophageal Junction (GEJ) Cancer+1 more

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07660055

Phase 1

Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Pilot Feasibility Trial

This pilot feasibility clinical trial is evaluating a novel treatment strategy for patients with advanced bladder cancer that is unresectable, has spread to ne…

Muscle Invasive Bladder CarcinomaStage III Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8

Estimated

~$10 – $6,250

University of WashingtonNCT07579195

Phase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with…

Non-muscle Invasive Bladder Cancer

Estimated

~$10 – $8,750

Protara TherapeuticsNCT05951179

Predicting Outcomes in Intermediate and High-risk Non-muscle Invasive Bladder Cancer Using Automated Analysis of Digital Pathology Data

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness t…

Non-muscle-invasive Bladder Cancer

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT05825950

Observational

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episo…

Breast CancerCervical CancerBladder Cancer+4 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT07227077

Phase 2

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplat…

Urothelial CancerBladder Cancer

Estimated

~$10 – $7,500

Daiichi SankyoNCT07129993

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic min…

Bladder CarcinomaGastric CarcinomaLiver and Intrahepatic Bile Duct Carcinoma+2 more

Estimated

~$10 – $750

University of California, DavisNCT04410302

Phase 3

COMparative Prospective Assessment Through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial

The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved…

Non-Muscle Invasive Bladder Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06929286

Phase 2

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or …

Nonmuscle-invasive Bladder Cancer

Estimated

~$10 – $8,750

ImmVira Pharma Co. LtdNCT06971614

Phase 3

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypo…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$10 – $7,500

NRG OncologyNCT07097142